[Tinea capitis occurring in a preschool environment].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to F Poujade.
Explore the source record for details and available documents.
PHARMACOKINETICS PHARMACODYNAMICS: Methadone is metabolized by cytochrome P450 enzymes in the liver microsomes and binds selectively to mu opiate receptors. Drugs metabolized by these enzymes or mu receptor competitors can modify the action of methadone. Genetic polymorphism influences plasma concentrations of the active levo enantiomer and thus clinical efficacy. ANTITUBERCULOSIS DRUGS: Rifampicin lowers methadome plasma levels so dose must be adapted. Rifabutin does not affect methadone kinetics. ANTI-EPILEPSY DRUGS: Phenytoin lowers blood levels of methadone by about 50% in 3 to 4 days. Other anti-epilepsy enzyme inducers (phenobarbital, carbamazepine) increase methadone metabolism. ANTI-VIRAL DRUGS: The area under the curve of plasma concentrations of zidovudine in presence of methadone increase by 43%, increasing the risk of undesirable effects. PSYCHOTROPES: Plasma levels of methadone increase by 20 to 100% in the presence of fluvoxamine. The benzodiazepine-methadone combination can be fatal due to respiratory depression. OTHER DRUGS: Brupenophine is a methadone agonist at the dose of 1 and 2 mg. Chronic alcoholism reduces the area under the curve while acute alcoholism increases it. Pure morphine agonists raise a major risk of respiratory depression while partial agonists favor the development of withdrawal symptoms.
On the basis of epidemiologic and clinical data in humans, and of experimental studies in kittens, E. Brumpt in 1925 showed that Entamoeba histolytica producing quadrinucleate cysts was a complex of 2 species. He differentiated a pathogenic and invasive form, from a non pathogenic and non invasive one that he called Entamoeba dispar. His explanation gained little support until recently, when Sargeaunt reported a study of isoenzyme typing and allow then the classification of amoebae resembling E. histolytica in pathogenic and non pathogenic species. Monoclonal antibodies and PCR have recently been used and have shown to react specifically with the two forms of amoebae. Genetic evidence has also demonstrated that the pathogenic and non pathogenic amoebae represent different species.